- Home
- About Us
- Committees
- Programs
- Online Library
- Resources
- Brain Exchange
NewsWe believe everyone living with Multiple Sclerosis across the world should have equal and affordable access to disease-modifying therapies (DMTs). Read more about MS International Federation MSIF and World Health Organization Collaborating Centre Bologna's application to add MS treatments to the World Health Organization's Essential Medicines List (EML) in Lancet Neurology. The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) congratulates the International Advisory Committee on Clinical Trials (IACCT) in MS on their creation of a proposed framework redefining how different types of multiple sclerosis are described. This new framework will be instrumental in being able to better understand and treat MS in the future. The paper by Tanja Kuhlmann, MD (University Hospital Münster, Germany) and collaborators was published today in Lancet Neurology on behalf of the IACCT. ACTRIMS supports the panel’s proposal to understand MS as a continuous disease process and agrees that having a biological understanding of what drives any individual’s disease course will lead to better, more personalized treatments. The International Advisory Committee on Clinical Trials in MS, a long-standing initiative jointly supported by ECTRIMS and the National MS Society (USA) and includes many current and former ACTRIMS board members. The Committee provides perspective and guidance in areas of interest to planning and implementation of clinical trials for new agents for the treatment of multiple sclerosis. The International Neurotoxin Association (INA) has scheduled the “TOXINS 2022 6th International Conference”. This In-Person TOXINS 2022 Conference is taking place July 27-30, 2022 in New Orleans, LA, USA. The INA is a not-for-profit, international scientific society dedicated to advancing scientific research, supporting education, and fostering understanding about botulinum and other neurotoxins. The INA provides a forum for the exchange of information and ideas among scientists, clinicians, and other allied health professionals about the science and therapeutic use of neurotoxins. Date: July 27-30, 2022
The Atlas of MS showed that off-label disease-modifying therapies are used in at least 89 countries. This highlights the need for structured and transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions. The authors put forward general principles for the ethical use of off-label DMTs for treating MS and a process to assess existing evidence and develop recommendations for their use in this manuscript. The principles and process are endorsed by the World Federation of Neurology (WFN), American Academy of Neurology (AAN), European Academy of Neurology (EAN), Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Middle-East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) and Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS). Research led by investigators at The Ohio State University Wexner Medical Center provides new hope for recovery from degenerative neurological diseases, such as multiple sclerosis. Using a mouse model, researchers at Ohio State and the University of Michigan discovered a new type of immune cell that not only rescues damaged nerve cells from death but partially reverses nerve fiber damage. The research team also identified a human immune cell line, with similar characteristics, that promotes nervous system repair.
Learn more here:
To all our volunteers, we appreciate all you do!
Association Forum awarded ACTRIMS Managing Director, Jen Brydges, the prestigious Forty Under 40 award for her commitment to the industry, leadership skills and continued potential. Congratulations Jen! New Chair Aims to Keep ACTRIMS Up to Pace with Dynamism of the Multiple Sclerosis Field Dr. Jeffrey Cohen on ACTRIMS Forum 2019 and trends in the subspecialty. Spinal cord atrophy found to be accelerated in subset of RRMS patients DALLAS – The rate of spinal cord atrophy at the C1 level is promising as a prognostic biomarker for the future conversion to secondary progressive disease in patients with relapsing remitting multiple sclerosis (RRMS), results from a novel, single-center study suggest. Smartphone-based visual tests for MS patients show promise DALLAS – A battery of smartphone-based tests has been developed to help detect visual pathway disturbances in MS patients and to follow them over time. Large survey reveals that few MS patients have long-term care insurance DALLAS – A number of sociodemographic factors may influence health and disability insurance access by individuals with multiple sclerosis, including employment, age, gender, disease duration, marital status, and ethnicity, results from a large survey suggest. The International Neurotoxin Association (INA) has scheduled the “TOXINS 2022 6th International Conference”. This In-Person TOXINS 2022 Conference is taking place July 27-30, 2022 in New Orleans, LA, USA.
The INA is a not-for-profit, international scientific society dedicated to advancing scientific research, supporting education, and fostering understanding about botulinum and other neurotoxins. The INA provides a forum for the exchange of information and ideas among scientists, clinicians, and other allied health professionals about the science and therapeutic use of neurotoxins.
Date: July 27-30, 2022 Location: New Orleans, LA, USA Website: www.neurotoxins.org |
